| Ventricular lead . | Patient population . | ||
|---|---|---|---|
| . | Standard impedance . | High impedance . | Significance . |
| Number of patients | 10 | 6 | NS |
| Age (years) | 72 ± 13 | 74 ± 11 | NS |
| Female | 6 (60%) | 3 (50%) | NS |
| Follow-up (months) | 86.7 ± 6.8 | 92.8 ± 10.3 | NS |
| Indication for pacing | |||
| AV-block | 1 | 1 | NS |
| Sinus node disease | 9 | 5 | NS |
| Coronary heart disease | 0 | 0 | NS |
| Valvular heart disease | 0 | 0 | NS |
| Diabetes mellitus | 0 | 1 | NS |
| Hypertension | 5 (50%) | 2 (33%) | NS |
| Ejection fraction (%) | 52 ± 13 | 50 ± 8 | NS |
| ASVS (%) | 3.2 ± 7.3 | 1.6 ± 4.5 | NS |
| ASVP (%) | 36.8 ± 42.3 | 38.3 ± 69.3 | NS |
| APVS (%) | 0.6 ± 1.3 | 0.5 ± 1.1 | NS |
| APVP (%) | 57.8 ± 43.4 | 58.6 ± 26.4 | NS |
| Ventricular lead . | Patient population . | ||
|---|---|---|---|
| . | Standard impedance . | High impedance . | Significance . |
| Number of patients | 10 | 6 | NS |
| Age (years) | 72 ± 13 | 74 ± 11 | NS |
| Female | 6 (60%) | 3 (50%) | NS |
| Follow-up (months) | 86.7 ± 6.8 | 92.8 ± 10.3 | NS |
| Indication for pacing | |||
| AV-block | 1 | 1 | NS |
| Sinus node disease | 9 | 5 | NS |
| Coronary heart disease | 0 | 0 | NS |
| Valvular heart disease | 0 | 0 | NS |
| Diabetes mellitus | 0 | 1 | NS |
| Hypertension | 5 (50%) | 2 (33%) | NS |
| Ejection fraction (%) | 52 ± 13 | 50 ± 8 | NS |
| ASVS (%) | 3.2 ± 7.3 | 1.6 ± 4.5 | NS |
| ASVP (%) | 36.8 ± 42.3 | 38.3 ± 69.3 | NS |
| APVS (%) | 0.6 ± 1.3 | 0.5 ± 1.1 | NS |
| APVP (%) | 57.8 ± 43.4 | 58.6 ± 26.4 | NS |
Values are mean ± SD.
ASVS, percentage of atrial sensed/ventricular sensed events; ASVP, percentage of atrial sensed/ventricular paced events; APVS, percentage of atrial paced/ventricular sensed events; APVP, percentage of atrial paced/ventricular paced events.
| Ventricular lead . | Patient population . | ||
|---|---|---|---|
| . | Standard impedance . | High impedance . | Significance . |
| Number of patients | 10 | 6 | NS |
| Age (years) | 72 ± 13 | 74 ± 11 | NS |
| Female | 6 (60%) | 3 (50%) | NS |
| Follow-up (months) | 86.7 ± 6.8 | 92.8 ± 10.3 | NS |
| Indication for pacing | |||
| AV-block | 1 | 1 | NS |
| Sinus node disease | 9 | 5 | NS |
| Coronary heart disease | 0 | 0 | NS |
| Valvular heart disease | 0 | 0 | NS |
| Diabetes mellitus | 0 | 1 | NS |
| Hypertension | 5 (50%) | 2 (33%) | NS |
| Ejection fraction (%) | 52 ± 13 | 50 ± 8 | NS |
| ASVS (%) | 3.2 ± 7.3 | 1.6 ± 4.5 | NS |
| ASVP (%) | 36.8 ± 42.3 | 38.3 ± 69.3 | NS |
| APVS (%) | 0.6 ± 1.3 | 0.5 ± 1.1 | NS |
| APVP (%) | 57.8 ± 43.4 | 58.6 ± 26.4 | NS |
| Ventricular lead . | Patient population . | ||
|---|---|---|---|
| . | Standard impedance . | High impedance . | Significance . |
| Number of patients | 10 | 6 | NS |
| Age (years) | 72 ± 13 | 74 ± 11 | NS |
| Female | 6 (60%) | 3 (50%) | NS |
| Follow-up (months) | 86.7 ± 6.8 | 92.8 ± 10.3 | NS |
| Indication for pacing | |||
| AV-block | 1 | 1 | NS |
| Sinus node disease | 9 | 5 | NS |
| Coronary heart disease | 0 | 0 | NS |
| Valvular heart disease | 0 | 0 | NS |
| Diabetes mellitus | 0 | 1 | NS |
| Hypertension | 5 (50%) | 2 (33%) | NS |
| Ejection fraction (%) | 52 ± 13 | 50 ± 8 | NS |
| ASVS (%) | 3.2 ± 7.3 | 1.6 ± 4.5 | NS |
| ASVP (%) | 36.8 ± 42.3 | 38.3 ± 69.3 | NS |
| APVS (%) | 0.6 ± 1.3 | 0.5 ± 1.1 | NS |
| APVP (%) | 57.8 ± 43.4 | 58.6 ± 26.4 | NS |
Values are mean ± SD.
ASVS, percentage of atrial sensed/ventricular sensed events; ASVP, percentage of atrial sensed/ventricular paced events; APVS, percentage of atrial paced/ventricular sensed events; APVP, percentage of atrial paced/ventricular paced events.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
